The France PECAN Digital Therapeutics and Telemonitoring Market was valued at approximately USD 312 Million. It is projected to grow at a CAGR of around 15.7% during the forecast period of 2026–2030, reaching an estimated USD 646.88 Million by 2030.
The France PECAN Digital Therapeutics and Telemonitoring Market includes all clinically validated digital care and remote patient monitoring (RPM) solutions in France's changing reimbursement and healthcare delivery systems. The market comprises software-based therapeutic options, networks of connected monitoring and digital care management solutions to enable ongoing care utilisation and clinical management. It does not include consumer wellness applications, non-clinical fitness devices or standalone hardware products that do not directly facilitate the delivery of monitored healthcare or therapeutic results.
Digital health projects are now moving from the pilot stage to a more structured approach to integration into clinical pathways. Healthcare providers are increasingly prioritising solutions that can show clinical value through measurable outcomes, increase patient adherence and facilitate care delivery beyond the hospital setting. Meanwhile, emerging connected technologies, data processing and analysis power, and remote monitoring infrastructure are allowing for more individualised and proactive patient care for chronic and complex diseases.
The market isn't just about technology anymore; it's about how it can be scaled, sustainable reimbursement and clinical impact for decision-makers. The skill of mapping out digital solutions with provider workflows, funding opportunities, and long-term patient outcomes becomes a key determinant of success. Evaluating opportunities within this area requires robust research and evidence, as well as preparedness for implementation and an understanding of the changing healthcare landscape to work out where digital care can be sustainably and economically beneficial.
Key Market Insights
Research Methodology
Scope & Definitions
Evidence Collection (Primary + Secondary)
Triangulation & Validation
Presentation & Auditability
France PECAN Digital Therapeutics and Telemonitoring Market Drivers
Healthcare providers are placing increased focus on digitally supported chronic care pathways.
Healthcare organisations are more and more modernising the management of chronic diseases, incorporating digitally connected care pathways to provide continuous patient engagement outside of the clinical environment. Digital therapeutics and telemonitoring solutions can assist in automating routine follow-ups, care coordination and enhancing treatment visibility. This adaptation allows for better use of resources and helps health care professionals to allocate their time to more clinically relevant activities.
Automation of healthcare workflows is being driven by connected monitoring technologies.
The rise of connected monitoring ecosystems is shaping how patient data is gathered, analysed and acted on across healthExchange Use Case s. Automated data collection minimises administration, enhances clinical responsiveness and facilitates earlier identification of patient condition changes. Healthcare providers are seeking to modernise their operations, and telemonitoring is becoming part of the technological infrastructure for scalable and digitally enabled care delivery.
There is growing confidence in investments in digital care due to the reinforcement of reimbursement frameworks.
The structured reimbursement mechanisms are helping to establish a more predictable environment for healthcare providers and technology developers investing in digital care solutions. More financial visibility helps to drive widespread adoption of telemonitoring and digital therapeutic programmes and assists with long-term modernisation goals. This framework is an ongoing process that will promote faster adoption by ensuring clinical innovation, operational efficiency and sustainable healthcare delivery models are aligned.
France PECAN Digital Therapeutics and Telemonitoring Market Restraints
However, the market is still grappling with difficult reimbursement qualification burdens, a wide range of healthcare IT systems, clinician workflow challenges and inconsistent patient digital literacy. Some vendors are still facing the challenge of demonstrating long-term clinical and economic value, and data privacy expectations are still high, challenging the vision of widespread adoption across the healthcare system.
France PECAN Digital Therapeutics and Telemonitoring Market Opportunities
Expansion of outcome-based reimbursement models, integration of PECAN with care coordination platforms, upsurge of demand for remote chronic disease supervision and the use of predictive analytics are opportunities that exist in France's PECAN and digital therapeutics/telemonitoring environment. There is value to be realised by market participants to increase the efficiency of the clinical workflow, patient engagement, and improvements in tangible healthcare metrics.
Patients with chronic conditions are identified through hospital, outpatient, or primary care pathways.
Clinicians evaluate whether digital therapeutic intervention or telemonitoring is appropriate.
Clinical evidence and reimbursement eligibility are reviewed before deployment.
Physicians prescribe approved digital therapeutic or monitoring solutions where applicable.
Mobile applications, web platforms, connected devices, or cloud-based systems are activated.
Remote physiological data, patient-reported outcomes, and adherence information are collected.
Healthcare teams review alerts, trends, and treatment adherence indicators.
Care plans are modified based on patient progress and monitoring insights.
Clinical outcomes and utilization data support reimbursement requirements.
Solutions continue across hospital, outpatient, primary care, home care, and rehabilitation environments.
Why this market matters now
The most important shift in France is the transition from innovation funding toward evidence-backed reimbursement.
Many digital health vendors previously focused on proving technological capability. Today, decision-makers focus on clinical validation, physician acceptance, workflow integration, and reimbursement sustainability.
Healthcare systems continue to face workforce shortages, increasing chronic disease prevalence, and pressure to manage patients outside hospitals. Telemonitoring and digital therapeutics offer potential efficiency gains, but only when they fit existing care pathways.
This creates a more demanding market environment. Vendors must prove outcomes. Providers must justify implementation effort. Payers must validate value creation.
As a result, reimbursement readiness is becoming a stronger competitive advantage than product novelty.
What matters most when evaluating claims in this market
|
Claim type |
What good proof looks like |
What often goes wrong |
|
Clinical effectiveness |
Peer-reviewed outcome evidence and real-world results |
Reliance on small pilot studies |
|
Reimbursement readiness |
Clear pathway alignment and economic justification |
Assuming approval guarantees adoption |
|
Physician adoption |
Documented workflow integration and utilization |
Ignoring clinician workload impact |
|
Patient engagement |
Sustained adherence and retention metrics |
Measuring downloads instead of usage |
|
Telemonitoring value |
Reduced intervention delays and improved management |
Overstating monitoring without outcomes |
|
AI-enabled monitoring |
Transparent validation and clinical oversight |
Treating algorithms as standalone evidence |
The decision lens
1. Define Market Boundary
Confirm whether revenues originate from reimbursed digital care activities rather than adjacent wellness services.
2. Verify Evidence Quality
Compare clinical validation standards across therapeutic categories and Exchange Use Case s.
3. Assess Reimbursement Fit
Determine whether solutions align with current reimbursement pathways and funding structures.
4. Evaluate Workflow Impact
Measure implementation complexity for hospitals, clinicians, and care networks.
5. Stress-Test Adoption
Review physician acceptance, patient engagement, and retention risks.
6. Compare Platform Scalability
Assess integration across mobile, web, wearable, and cloud environments.
7. Monitor Policy Timing
Identify reimbursement, regulatory, and procurement developments that may alter adoption speed.
The contrarian view
Many market assessments assume that reimbursement automatically creates demand.
That assumption is often wrong.
A reimbursed solution may still struggle if physicians find workflows burdensome or patients fail to engage consistently.
Another common mistake is combining digital therapeutics, telehealth, wellness applications, and connected devices into a single opportunity estimate. This can create hidden double counting and inflated forecasts.
Many analyses also overemphasize technology innovation while underestimating evidence generation costs, provider adoption challenges, and operational integration requirements.
The strongest opportunities often emerge where reimbursement, clinical evidence, and physician workflows align simultaneously.
Practical implications by stakeholder
Digital Therapeutics Vendors
Telemonitoring Providers
Hospitals and Health Systems
Payers and Reimbursement Authorities
Investors and Strategic Buyers
Physicians and Care Networks
FRANCE PECAN DIGITAL THERAPEUTICS AND TELEMONITORING MARKET REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2025 - 2030 |
|
Base Year |
2025 |
|
Forecast Period |
2026 - 2030 |
|
CAGR |
15.7% |
|
Segments Covered |
By Therapeutic Area , Monitoring Modality, Care Setting , Reimbursement & Funding Model , Technology Platform , and Region |
|
Various Analyses Covered |
Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regional Scope |
Europe, France |
|
Key Companies Profiled |
Cureety, Diabeloop, Voluntis, Doctolib, Withings, BioSerenity, Implicity, Wefight, Resilience (Resilience Care), Cegedim Health Data, Sanofi, Air Liquide Healthcare, Philips France, Medtronic France, and Minze Health |
France PECAN Digital Therapeutics and Telemonitoring Market Segmentation
Diabetes Management enjoyed the biggest therapeutic area market share at 31.8% of the market. Demand for remote glucose monitoring and the presence of clinical paths endured across the country and among health care providers and patients alike.
The fastest-growing segment was neurology & mental health management, which is expected to grow through 2030. The 10.2% market share highlights its increasing acceptance in the market, enhanced accessibility, and increased focus on long-term behavioural healthcare.
PECAN Reimbursed Solutions reaped the lowest share of funding (39.6%) but the highest share of reimbursements. Digital therapeutics deployments nationwide experienced an increase in provider participation, investment confidence, and formal reimbursement mechanisms, which helped to increase commercial certainty.
PECAN Reimbursed Solutions is also the fastest-growing funding segment over the forecast period. Growth momentum is also continuing to be reinforced through expanded eligibility, increased clinical validation requirements and greater acceptance within the healthcare system.
Île-de-France was the region with the highest market activity (34%). The region has a strong capacity for innovation, advanced digital health ecosystems, and provider adoption, which leads to sustained leadership, and concentrated healthcare infrastructure, which benefits the region.
Occitanie is expected to be the region with the highest growth until 2030. It is now present in 12% of the market, and its share continues to grow thanks to the increasing institutionalisation of healthcare digitisation projects, investments in remote healthcare, and chronic disease management.
Latest Market News
A new ministerial order was published on 28 November 2025 to further extend the PECAN early reimbursement mechanism in France, further strengthening access for digital therapeutics and telemonitoring solutions, which are available under 2 dedicated reimbursement pathways launched since 2023.
On September 10, 2025, the French health technology assessment agency released formal guidance on the evaluation principles for digital medical devices for two pathways for reimbursement that were developed based on experiences from the submissions since 2023.
The National Telemonitoring Guidance subsequently reaffirmed the reimbursement eligibility of telemonitoring services for 6 major disease categories, including diabetes, oncology, respiratory disease, renal disease, heart failure, and cardiac arrhythmia.
The PECAN continued to further develop the adoption of digital therapeutics in France, with international benchmarking showing 59 digital therapeutics that are reimbursed in Germany and an emerging reimbursement landscape in France.
The medical telemonitoring reimbursement is provided to Continuum+ Connect with PECAN coverage and will be valid for 1 year, with a reimbursement application needed within 9 months of program start.
On 13 September 2024, a ministerial order was issued by France to support early reimbursement of certain digital therapeutics and telemonitoring activities in order to better implement Article L.162-1-23 of the Social Security Code.
France clarified the reimbursement compensation for digital therapeutics with the PECAN (reimbursement for health promotion and prevention technologies), a payment of €435 for the first 3 months followed by a monthly payment of €38.30 from month 4.
Mar 20, 2024: A new tariff order for activities included in the national telemonitoring framework was released by French authorities to update rules for reimbursement of telemonitoring.
Key Players
Questions buyers ask before purchasing this report
Is PECAN reimbursement enough to guarantee commercial success?
No. Reimbursement improves market access, but adoption depends on physician acceptance, clinical evidence, patient engagement, and operational fit. The report helps separate reimbursed opportunities from commercially scalable opportunities.
Which therapeutic areas are likely to create the strongest demand?
Demand varies by disease burden, monitoring requirements, reimbursement alignment, and provider adoption. The report evaluates how different therapeutic categories contribute to market development rather than assuming equal growth potential.
How important is physician prescription readiness?
It is often one of the most important adoption variables. Solutions that fit naturally into clinical workflows generally achieve stronger utilization than products requiring significant behavioral change from clinicians.
What makes telemonitoring different from standard digital health tools?
Telemonitoring generates ongoing clinical insight that can influence patient management. The distinction matters because reimbursement, adoption, and outcome expectations differ significantly from general digital health applications.
How should buyers evaluate evidence quality?
Buyers should focus on outcome relevance, study quality, real-world performance, and clinical applicability. Strong evidence supports both reimbursement sustainability and long-term adoption.
What risks are commonly overlooked in this market?
Many organizations underestimate integration costs, physician adoption barriers, patient engagement challenges, and reimbursement evolution. These factors often determine actual commercial outcomes.
How does the report help investment decisions?
The report identifies where reimbursement, adoption readiness, and clinical validation intersect. This helps investors prioritize opportunities with stronger long-term commercial potential.
Why is market segmentation important in this sector?
Different therapeutic areas, Exchange Use Case s, technology platforms, and funding structures operate under distinct adoption dynamics. Segmentation helps prevent misleading comparisons and improves strategic decision-making.
The France PECAN Digital Therapeutics and Telemonitoring Market was valued at approximately USD 312 Million. It is projected to grow at a CAGR of around 15.7% during the forecast period of 2026–2030, reaching an estimated USD 646.88 Million by 2030.
The major drivers of the France PECAN Digital Therapeutics and Telemonitoring Market include the growing focus on digitally supported chronic care pathways, increasing adoption of connected monitoring technologies, and strengthening reimbursement frameworks for digital healthcare solutions. Healthcare providers are increasingly leveraging digital therapeutics and telemonitoring platforms to improve patient engagement, automate routine follow-ups, enhance care coordination, and support continuous disease management beyond traditional healthExchange Use Case s. Additionally, the expansion of reimbursement mechanisms and the growing emphasis on operational efficiency, proactive patient monitoring, and scalable healthcare delivery models continue to accelerate market growth across France.
Diabetes Management, Cardiovascular Disease Management, Respiratory Disease Management, Oncology Support & Symptom Monitoring, Neurology & Mental Health Management, and Others are the segments under the France PECAN Digital Therapeutics and Telemonitoring Market by Therapeutic Area. Remote Physiological Monitoring, Therapeutic Adherence Monitoring, Connected Medical Device-Based Monitoring, Patient-Reported Outcome Monitoring, AI-Enabled Predictive Monitoring, and Others are the segments by Monitoring Modality. Hospital-Based Care, Ambulatory & Outpatient Care, Primary Care Networks, Home-Based Care, Long-Term Care & Rehabilitation Facilities, and Others are the segments by Exchange Use Case . Mobile Application-Based Platforms, Web-Based Clinical Platforms, Connected Wearables Platforms, Medical Device-Integrated Platforms, Cloud-Based Care Management Platforms, and Others are the segments by Technology Platform. PECAN Reimbursed Solutions, National Health Insurance-Funded Programs, Hospital-Funded Deployments, Regional Health Authority-Funded Programs, Private Insurance-Supported Programs, and Others are the segments by Reimbursement & Funding Model. Île-de-France, Auvergne-Rhône-Alpes, Provence-Alpes-Côte d’Azur, Occitanie, and Remaining France are the regional segments under the France PECAN Digital Therapeutics and Telemonitoring Market.
Île-de-France is the most dominant region in the France PECAN Digital Therapeutics and Telemonitoring Market, supported by its advanced healthcare infrastructure, strong concentration of digital health innovators, extensive healthcare provider networks, and high adoption of telemonitoring and digital therapeutic solutions. Occitanie is expected to be the fastest-growing region during the forecast period of 2026–2030, driven by expanding healthcare digitization initiatives, growing investments in remote care infrastructure, and increasing deployment of chronic disease management programs. Auvergne-Rhône-Alpes, Provence-Alpes-Côte d’Azur, and Remaining France continue to experience steady growth due to ongoing modernization of healthcare delivery and increasing utilization of connected care technologies.
The key players in the France PECAN Digital Therapeutics and Telemonitoring Market include Cureety, Diabeloop, Voluntis, Doctolib, Withings, BioSerenity, Implicity, Wefight, Resilience (Resilience Care), Cegedim Health Data, Sanofi, Air Liquide Healthcare, Philips France, Medtronic France, and Minze Health.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Specify your preferred Countries, Segments, or timeframes
Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.
